Atlantic Urological Associates

Daytona Beach, Florida 32114

0 studies enrolling now · 13 studies all time

What they study most

Benign Prostatic Hypertrophy, Bladder Cancer, Bladder Cancer Recurrence, Dietary Hyperoxaluria, Fractures, Hyperoxaluria, Interstitial Cystitis, Kidney Stones, Microscopic or Gross Hematuria, Nephrolithiasis, Osteoporosis, Preneoplastic Conditions

Studies at this site

• Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) — Completed
• Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) — Stopped early
• Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones — Completed
• The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy — Completed
• Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer — Completed
• Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days — Completed
• Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis — Stopped early
• Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy — Completed
• Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer — Status unconfirmed
• Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer — Completed
• Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer — Completed
• Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis — Completed
• Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer — Completed